#news
-
NOVITÀ
Health Canada Approves REBLOZYL® For Adult Patients with β-Thalassaemia
Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. announced today that Health Canada has approved REBLOZYL® (luspatercept) for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia…
Leggi di più » -
NOVITÀ
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
Leggi di più » -
NOVITÀ
Iranian Blood Transfusion Organization Newsletter – August 2020
The Iranian Blood Transfusion Organization (IBTO) and its most recent activities are featured on TIF’S website.
Leggi di più » -
NOVITÀ
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
Leggi di più » -
NOVITÀ
TIF’s Latest Newsletter Issue Is Out!
Our August 2020 newsletter has just been published! Read about our latest updates, including country activities, international projects, educational updates for patients with thalassaemia and haemoglobin disorders, and our novel…
Leggi di più » -
NOVITÀ
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
Leggi di più » -
NOVITÀ
Thalassemics India News Update
The latest news from TIF’s Member ”Thalassemics India” in one place! In this issue you will find all the information on the new Thalassaemia Screening & Counselling Center in New…
Leggi di più » -
NOVITÀ
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…
Leggi di più » -
NOVITÀ
Malaysian Health Minister: The Country Needs More Geneticists to Detect Thalassaemia Early
Malaysia needs more geneticists in order to identify thalassaemia patients at an early stage, stated Health Minister Datuk Seri Dr Adham Baba, after launching the 2019 Malaysia Thalassaemia Registry (MTR)…
Leggi di più » -
NOVITÀ
The eThalED Course Webinar Series Return With a New Session on Iron Monitoring in Thalassaemia
TIF´s upcoming webinar on ”Iron Monitoring in Thalassaemia”, specially designed and launched for medical specialists and healthcare professionals with a particular interest in the field of haemoglobin disorders and thalassaemia,…
Leggi di più »